ERBB2 and breast cancer: However, increased GPAT expression, which would be predicted to increase lysophosphatidate levels, is observed in melanoma, lung, prostate, and breast cancer and is associated with shorter overall survival in ovarian cancer and shorter disease-free survival in HER2-positive breast cancer [229].